References
- Hennessy S, Leonard CE, Platt R. Assessing the safety and comparative effectiveness of follow-on biologics (biosimilars) in the United States. Clin Pharmacol Ther 2010;87:157-9
- Varkony H, Weinstein V, Klinger E, et al. The glatiramoid class of immunomodulator drugs. Expert Opin Pharmacother 2009;10:657-68
- Johnson KP. Glatiramer acetate and the glatiramoid class of immunomodulator drugs in multiple sclerosis: an update. Expert Opin Drug Metab Toxicol 2010;6:643-60
- Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol 2008;19:411-19
- Chirino AJ, Mire-Sluis A. Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol 2004;22:1383-91
- Chugh PK, Roy V. Biosimilars: current scientific and regulatory considerations. Curr Clin Pharmacol 2014;9:53-63
- Kuhlmann M, Covic A. The protein science of biosimilars. Nephrol Dial Transplant 2006;21(Suppl 5):v4-8; 33
- Declerck PJ. Biosimilar monoclonal antibodies: a science-based regulatory challenge. Expert Opin Biol Ther 2013;13:153-6
- Cai XY, Thomas J, Cullen C, Gouty D. Challenges of developing and validating immunogenicity assays to support comparability studies for biosimilar drug development. Bioanalysis 2012;4:2169-77
- Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 2003;348:601-8
- Schellekens H. Immunologic mechanisms of EPO-associated pure red cell aplasia. Best Pract Res Clin Haematol 2005;18:473-80
- Lee H. Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars? AAPS J 2014;16:22-6
- Rosenberg AS. Immunogenicity of biological therapeutics: a hierarchy of concerns. Dev Biol 2003;112:15-21
- US Food and Administration. The patient protection and affordable care act. Available from: www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/therapeuticbiologicapplications/biosimilars/default.htm [Accessed 30 March 2015]
- European Medicines Agency. Guidelines on biosimilar products. Available from: www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000408.jsp#Overarchingbiosimilarguidelines [Accessed 30 March 2105]
- Biotechnology Industry Organization. Norma Oficial Mexicana PROY-NOM-177-SSA1. 2013. Available from: www.bio.org/sites/default/files/BIO%20Comments%20espa%C3%B1ol_0.pdf [Last accessed 30 March 2015]
- US Food and Drug Administration. Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product. Available from: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf [Accessed 31 January 2015]
- Choy E, Jacobs IA. Biosimilar safety considerations in clinical practice. Semin Oncol 2014;41(Suppl 1):S3-14
- Engelberg AB, Kesselheim AS, Avorn J. Balancing innovation, access, and profits–market exclusivity for biologics. N Engl J Med 2009;361(20):1917-19